Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections

Respirology

Volumn 14, Issue 5, 2009, Pages 746-752

  Chen, Ya Hong ^a   Yao, Wan Zhen ^a   Gao, Jing Zhen ^a   Geng, Bin ^b   Wang, Pei Pei ^a   Tang, Chao Shu ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antibiotic; Chronic obstructive pulmonary disease; Hydrogen sulfide; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; HYDROGEN SULFIDE;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; HYDROGEN SULFIDE; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; ROC CURVE;

EID: 68149107560     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01550.x     Document Type: Article

References (25)

1. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M et al. Guidelines for the management of adult lower respiratory tract infection. Eur. Respir. J. 2005 26 : 1138 80.
2. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Respir. Crit. Care Med. 2001 163 : 1730 54.
3. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc. Am. Thorac. Soc. 2004 1 : 109 14.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007 176 : 532 55.
5. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987 106 : 196 204.
6. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004 363 : 600 7.
7. Phua J, Koay ES, Zhang D, Tai LK, Boo XL et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur. Respir. J. 2006 28 : 695 702.
8. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 2004 39 : 206 17.
9. 2S be the third endogenous gaseous transmitter? FASEB J. 2002 16 : 1792 8.
10. Collin M, Anuar FB, Murch O, Bhatia M, Moore PK et al. Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br. J. Pharmacol. 2005 146 : 498 505.
11. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006 20 : 2118 20.
12. Li L, Bhatia M, Moore PK. Hydrogen sulphide - a novel mediator of inflammation? Curr. Opin. Pharmacol. 2006 6 : 125 9.
13. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997 336 : 243 50.
14. 2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001 20 : 6008 16.
15. Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL et al. Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochem. Biophys. Res. Commun. 2005 326 : 794 8.
16. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? J. Neurochem. 2004 90 : 765 8.
17. Geng B, Chang L, Pan C, Qi Y, Zhao J et al. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem. Biophys. Res. Commun. 2004 318 : 756 63.
18. Bhatia M, Wong FL, Fu D, Lau HY, Moochhala SM et al. Role of hydrogen sulfide in acute pancreatitis and associated lung injury. FASEB J. 2005 19 : 623 5.
19. Zhang H, Zhi L, Moore PK, Bhatia M. The role of hydrogen sulfide in cecal ligation and puncture induced sepsis in the mouse. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006 290 : L1193 201.
20. Chen YH, Yao WZ, Geng B, Ding YL, Lu M et al. Endogenous hydrogen sulfide in patients with COPD. Chest 2005 128 : 3205 11.
21. Zhang QY, Du J, Zhou W, Yan H, Tang CS et al. Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. Biochem. Biophys. Res. Commun. 2004 317 : 30 7.
22. Mitsuhashi H, Yamashita S, Ikeuchi H, Kuroiwa T, Kaneko Y et al. Oxidative stress-dependent conversion of hydrogen sulfide to sulfite by activated neutrophils. Shock 2005 24 : 529 34.
23. Rinaldi L, Gobbi G, Pambianco M, Micheloni C, Mirandola P et al. Hydrogen sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. Lab. Invest. 2006 86 : 391 7.
24. Hu LF, Wong PT, Moore PK, Bian JS. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J. Neurochem. 2007 100 : 1121 8.
25. Liu YN, Chen MJ, Zhao TM, Wang H, Wang R et al. A multicenter study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China. Chin. J. Tuberc. Respir. Dis. 2006 29 : 3 8.